Zimmer Partners LP Buys Shares of 10,000 Immunocore Holdings plc (NASDAQ:IMCR)

Zimmer Partners LP bought a new stake in Immunocore Holdings plc (NASDAQ:IMCR) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $426,000.

Other hedge funds also recently made changes to their positions in the company. Laurion Capital Management LP purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $213,000. Victory Capital Management Inc. purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $426,000. UBS Group AG purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $497,000. Caas Capital Management LP purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $639,000. Finally, Morgan Stanley acquired a new stake in shares of Immunocore in the 1st quarter valued at approximately $648,000. Institutional investors own 35.17% of the company’s stock.

Separately, Zacks Investment Research cut Immunocore from a “hold” rating to a “sell” rating in a report on Wednesday, May 26th.

Shares of IMCR traded up $0.03 during mid-day trading on Thursday, hitting $35.70. The company’s stock had a trading volume of 128,704 shares, compared to its average volume of 54,799. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.23 and a quick ratio of 6.23. The business has a 50-day moving average of $38.29. Immunocore Holdings plc has a 1-year low of $30.92 and a 1-year high of $61.99.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.13). The firm had revenue of $11.41 million during the quarter, compared to analyst estimates of $8.38 million. Research analysts anticipate that Immunocore Holdings plc will post -4.14 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Read More: Do You Need a Fiduciary?

Institutional Ownership by Quarter for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.